Related Experiment Video

Updated: May 15, 2026

Using Retinal Imaging to Study Dementia
09:17

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

Metabolic syndrome and amnestic mild cognitive impairment: Singapore Longitudinal Ageing Study-2 findings

Liang Feng1, Mei Sian Chong, Wee Shiong Lim

  • 1Gerontology Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

Journal of Alzheimer'S Disease : JAD
|December 19, 2012
PubMed

Insights

Metabolic syndrome (MetS) increases the risk of amnestic mild cognitive impairment (aMCI). This association is stronger in individuals with the APOE-ε4 gene, particularly younger participants, highlighting a critical link between metabolic health and cognitive decline.

Area of Science:

  • Neurology
  • Gerontology
  • Metabolic Health

Background:

  • Metabolic syndrome (MetS) is linked to cognitive decline, but its specific association with Alzheimer's disease (AD) and amnestic mild cognitive impairment (aMCI) requires further investigation.
  • Existing evidence on MetS and aMCI is inconsistent, necessitating studies that explore modifying factors like APOE-ε4 status and age.

Purpose of the Study:

  • To examine the association between metabolic syndrome (MetS) and amnestic mild cognitive impairment (aMCI).
  • To investigate the influence of APOE-ε4 allele and younger age on the MetS-aMCI relationship.

Main Methods:

  • Logistic regression analysis was performed on data from the Singapore Longitudinal Ageing Study-2 (SLAS-2) cohort (n=98 aMCI, n=802 controls).
  • The study controlled for covariates including age, gender, education, lifestyle factors, and comorbidities.
  • Analyses were stratified by age and APOE-ε4 status to identify specific risk profiles.

Main Results:

  • Metabolic syndrome (MetS) was significantly associated with an elevated risk of amnestic mild cognitive impairment (aMCI) (OR = 1.79).
  • Central obesity, a component of MetS, independently predicted aMCI risk (OR = 1.77).
  • The association between MetS and aMCI was notably stronger in individuals carrying the APOE-ε4 allele (OR = 3.35), especially in younger participants (<65 years) with APOE-ε4 (OR = 6.57).

Conclusions:

  • Metabolic syndrome (MetS) is a significant risk factor for amnestic mild cognitive impairment (aMCI).
  • The APOE-ε4 genotype and younger age exacerbate the risk of aMCI in the presence of MetS.
  • These findings underscore the importance of metabolic health management, particularly for individuals with genetic predispositions, to mitigate cognitive decline risk.

More Related Videos

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...